- Home
- TRUG vs KPRX Comparison
TRUG vs KPRX Comparison
Compare TRUG & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUG
- KPRX
- Stock Information
- Founded
- TRUG 1983
- KPRX 1998
- Country
- TRUG United States
- KPRX United States
- Employees
- TRUG N/A
- KPRX N/A
- Industry
- TRUG
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TRUG
- KPRX Health Care
- Exchange
- TRUG NYSE
- KPRX Nasdaq
- Market Cap
- TRUG 8.4M
- KPRX 8.3M
- IPO Year
- TRUG N/A
- KPRX N/A
- Fundamental
- Price
- TRUG $0.24
- KPRX $2.98
- Analyst Decision
- TRUG Strong Buy
- KPRX Strong Buy
- Analyst Count
- TRUG 1
- KPRX 1
- Target Price
- TRUG $2.00
- KPRX $10.00
- AVG Volume (30 Days)
- TRUG 8.4M
- KPRX 9.8K
- Earning Date
- TRUG 05-15-2025
- KPRX 05-09-2025
- Dividend Yield
- TRUG N/A
- KPRX N/A
- EPS Growth
- TRUG N/A
- KPRX N/A
- EPS
- TRUG N/A
- KPRX N/A
- Revenue
- TRUG $22,236,072.00
- KPRX $20,000.00
- Revenue This Year
- TRUG $24.05
- KPRX N/A
- Revenue Next Year
- TRUG $31.65
- KPRX N/A
- P/E Ratio
- TRUG N/A
- KPRX N/A
- Revenue Growth
- TRUG 8.40
- KPRX N/A
- 52 Week Low
- TRUG $0.17
- KPRX $2.51
- 52 Week High
- TRUG $1.52
- KPRX $5.55
- Technical
- Relative Strength Index (RSI)
- TRUG 46.22
- KPRX 42.28
- Support Level
- TRUG $0.20
- KPRX $2.93
- Resistance Level
- TRUG $0.42
- KPRX $3.21
- Average True Range (ATR)
- TRUG 0.05
- KPRX 0.15
- MACD
- TRUG 0.00
- KPRX -0.03
- Stochastic Oscillator
- TRUG 25.14
- KPRX 29.02
About TRUG TRUGOLF HOLDINGS INC
TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games (including Links, a sports game for PC), hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.